Sangamo Therapeutics, Inc. (0R1D.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Sangamo Therapeutics, Inc.
Address
501 Canal Blvd
Richmond, CA 94005
United States of America (the)
Phone
510 970 6000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
183
First IPO Date
November 07, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Alexander D. Macrae Ch.B MRCP | Chief Executive Officer, President & Director | 930,255 | 1963 |
| Scott Willoughby | Senior Vice President, Chief Legal Officer & Corporate Secretary | 569,651 | 1975 |
| Nathalie Dubois-Stringfellow | Senior Vice President & Chief Development Officer | 585,224 | 1962 |
| Gregory Davis | Head of Research & Technology | 0 | 1970 |
| Stephanie J. Seiler | Vice President and Head of Business Development & Alliance Management | 0 | N/A |
| Phillip Ramsey | Chief Technical Officer | 0 | N/A |
| Louise Wilkie | Head of Global Corporate Communications & Investor Relations | 0 | N/A |
| Nikunj Jain | Interim CFO and Principal Financial & Accounting Officer | 0 | 1980 |
| David Ojala | Scientist II - Discovery & Translational Research | 0 | N/A |
Description
Sangamo Therapeutics, Inc. is a biotechnology firm currently in the clinical development phase, dedicated to converting scientific discoveries into groundbreaking genomic therapies. These therapies aim to significantly improve patients' lives, leveraging advanced platform technologies including gene therapy, cell therapy, genome editing, and genome regulation. Central to its operations is the zinc finger protein (ZFP) technology platform. This platform facilitates the creation of zinc finger nucleases, specialized proteins adept at altering DNA sequences by either inserting or deactivating particular genes. Additionally, it produces ZFP transcription factors, which are proteins utilized to either boost or diminish gene expression. The company's developmental pipeline includes several promising treatments: SB-525, currently undergoing Phase III AFFINE clinical trials for hemophilia A; ST-920, a gene therapy in Phase I/II STAAR clinical trials targeting Fabry disease; and SAR445136, a cell therapy undergoing Phase I/II PRECIZN-1 clinical trials for sickle cell disease. Further candidates in development are TX200, a chimeric antigen receptor designed to address HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for various cancers; ST-501 for tauopathies; and ST-502, intended for synucleinopathies such as Parkinson's disease and other neuromuscular conditions. Sangamo maintains numerous collaborative and strategic alliances with prominent entities such as Biogen MA, Inc., Kite Pharma, Inc., Pfizer Inc., Sanofi S.A., Novartis Institutes for BioMedical Research, Inc., Shire International GmbH, Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and the California Institute for Regenerative Medicine. Originally incorporated in 1995, the company operated under the name Sangamo BioSciences, Inc. until its renaming to Sangamo Therapeutics, Inc. in January 2017. Its corporate headquarters are located in Brisbane, California.
